AAN 2021 | Exciting trials in functional movement disorders
Alberto Espay, MD, FAAN, University of Cincinnati, Cincinnati, OH, discusses major ongoing trials on the field of functional movement disorders. Prof. Espay highlights the Physio4FMD randomized controlled trial (ISRCTN56136713) of physical-based rehabilitation for functional movement disorders. Several trials assessing cognitive behavioral therapy (CBT) are also underway, including a study of self-guided CBT delivered via an app. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Disclosures
Dr. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Neuroderm, Neurocrine, Amneal, Acadia, Acorda, Kyowa Kirin, Sunovion, Lundbeck, and USWorldMeds; honoraria from Acadia, Sunovion, Amneal, USWorldMeds; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics, owner of a patent application that covers synthetic soluble non-aggregating peptide analogues as replacement treatment in proteinopathies. He serves on the editorial boards of the Journal of Parkinson’s Disease, European Journal of Neurology, and JAMA Neurology.
